Aspen’s revenue increases 22% to R36 billion
Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the sixth largest generic company in the world, has announced excellent results for the year
Divestment of portfolio of branded and generic products to Strides entities
Aspen is pleased to announce that certain of its wholly owned Australian subsidiaries (collectively “Aspen Australia”), have entered into an agreement with Strides (Australia) Pharma
Cautionary Announcement
Shareholders are advised that Aspen is currently engaged in discussions regarding a possible acquisition of an infant nutritionals business. These discussions may have a material
Divestment of South African Business Unit to Litha
Aspen is pleased to announce that Pharmacare Limited (“Pharmacare”), a wholly owned subsidiary of Aspen Holdings and the Group’s primary South African trading company, has
Gauteng Premier’s visit to Aspen is set to boost export growth
Clayville, Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the 5th largest generic company in the world, earlier today hosted a delegation of
GSK announces completion of the sale of half its stake in Aspen
GlaxoSmithKline (“GSK”) has announced the completion of the disposal of half of its 12.4% shareholding in Aspen (equivalent to 28.2 million ordinary shares). These shares
Aspen’s half-year gross revenue surges by 47% to R19 billion
Aspen’s half-year gross revenue surges by 47% to R19 billion Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the fifth largest generic company
Acquisition of rights to an anti-coagulant product from Novartis
Aspen is pleased to announce that Aspen Global Incorporated (“AGI”), a wholly owned subsidiary of Aspen Holdings, has entered into an agreement with Novartis AG
Media Enquiries
Shauneen Beukes
Group Communications Consultant
+27 31 580 8600
+27 82 389 8900
sbeukes@aspenpharma.com
